Oxaliplatin Plus Hydroxycamptothecine Versus Oxaliplatin Plus 5-Fluorouracil and Leucovorin in Treatment of Advanced Colorectal Cancer.
Yao Yang,Sun Yuan-jue,Zhao Hui,Guo Yue-Wu,Lin Feng,Cai Xun,Tang Xiao-chun,Tang Li-na,Zhang Wei
DOI: https://doi.org/10.1097/00029330-200611010-00011
2006-01-01
Abstract:5-fluarouracil-based chemotherapy has become a standard regimen for the treatment of advanced colorectal cancer (ACRC).1 Defined as the second line therapy for ACRC with 5-fluarouracil (5-Fu) plus leucovorin (LV) combined with oxaliplatin (OXA), the response rate (RR), progression-free survival (PFS) and overall survival (OS) were 21.2%, at 4.7 and 11.5 months, whereas RR, PFS and OS with 5-Fu plus LV combined with irinotecan (CPT-11) were 11.4%, at 3.2 and 12.2 months. There were no statistical difference between the two protocals.2,3 Those results may well suggest that some of these patients were resistant to 5-Fu. Therefore it is necessary to find a more effective regimen without 5-Fu to treat recurrent ACRC patients that were initially treated with 5-Fu. Our previous study showed that OXA can enhance the function of hydroxycamptothecine (HCPT) in inducing the apoptosis of a human colorectal cell line in vivo.4 So we chose OXA plus HCPT (OH) regimen to treat 28 patients with ACRC and compared RR, one-year survival rate, PFS, OS and main toxicities with a 5-Fu plus LV combined with OXA (OFL) regimen. METHODS Eligibility criteria From March 2002 to August 2004, we identified 56 eligible patients with histologically confirmed adenocarcinoma and measurable lesions by CT scan, a Karnofsky Performance Status (KPS) ≥60 scores and an estimated life expectancy ≥3 months. No patients had had anticancer procedures within 1 month before the present study and had never had HCPT or OXA treatment before. Exclusive criteria was any of the following: hepatic, renal or cardiac dysfunction, white blood cell (WBC) count of < 4.0×109/L, a blood platelet count (BPC) < 100×109/L, encephalic or peripheral nervous system diseases. Patient characteristics are summarized in Table 1.Table 1: Comparison of the patient characteristic between OFL and OH groupsFifty-six eligible patients were randomly assigned to either the OH or the OFL group. After chemotherapy for each group WBC and BPC were determined every 3 days and hepatic and renal function tests were performed once a week. The lesions were measured by CT scan one week before chemotherapy and 4 weeks after the completion of two cycles of chemotherapy. This study was approved by the Ethics Committee of Human Research at Shanghai Sixth People's Hospital of Shanghai Jiaotong University, China. Every patient agreed to and signed an informed consent before the chemotherapy. Treatment In the OH group, the patients were treated with OXA 130 mg/m2 on day 1 plus HCPT 6 mg/m2 for 3-hour on days 1–4. In the OFL group, the patients were treated with OXA 130 mg/m2 plus LV 300 mg on day 1 immediately followed by 5-Fu 375 mg/m2 over 8 hours on days 1 - 5. The chemotherapy was administered by intravenous infusion and repeated every 3 weeks as a cycle. Every patient was treated with at least two cycles. The dose of OXA, HCPT and 5-Fu was reduced by 25% in subsequent courses in case any grade IV toxicity event might occur. Those patients with partial remission (PR) and stable disease (SD) were treated with the same chemotherapy regimen up to 6 cycles. For the patients with progressive disease (PD) after the initial two cycles of chemotherapy a second line therapy of CPT-11 plus 5-Fu regimen was administered up to 6 cycles. Eleven and ten patients received 109 and 116 cycles of the second line treatment in the OFL and OH groups, respectively. Follow-up After completion of two cycles of chemotherapy, 56 eligible patients were followed up every 4–6 weeks from 7 to 22 months ending in October 2005. Among them, 26 patients in the OFL group and 25 patients in the OH group completed a one-year follow-up. Twenty patients in the OFL group versus 17 patients in the OH group died within one year but 6 patients in the OFL group versus 8 patients in the OH group were alive. Up to October 2005, 3 and 4 patients were alive in OFL and OH groups, respectively. After an initial two cycles of chemotherapy for every patient, we assessed RR and toxicity in accordance with WHO criteria.5 TNM classification of ACRC was evaluated according to UICC criteria before the chemotherapy.6 Statistical analysis χ2 (Fisher's exact) test was used to assess RR and toxicity variation between the two groups and to determine the significance of the following prognostic variables: gender, age, KPS, TNM classification, previous and subsequent treatment. Survival curves were estimated using the Kaplan-Meier method, 95% confidence interval (95%CI) was calculated using the associated estimated standard errors.7 The Log-Rank test was used to compare PFS and OS in the two groups. The life table method was used to evaluate the one-year survival rate. RESULTS Treatment outcomes No significant differences were found between the two groups for KPS, age, gender or TNM classification before chemotherapy. No complete remission (CR) patients were found in either group. Using the χ2 (Fisher's exact) test, no significant differences were found for RR (CR+PR) in patients with stage III or stage IV disease nor between initial and re-treatment groups (Table 2). In the OFL group, 62.5% (5/8) patients with stage III achieved PR and had significant difference versus 10% (2/20) patients with stage IV (P=0.012).Table 2: Comparison of the response rate between OFL and OH groupsSurvival rate The one-year survival rate was 24.21% in the OFL group but it was 35.07% in the OH group. Median PFS and OS were 5.4 months and 8.7 months in the OFL group versus 6.1 months and 10.1 months in OH group (Figs. 1 and 2). However, there were no significant differences between the two groups' PFS and OS using a Log-Rank test (P=0.055, P=0.212, respectively).Fig. 1.: Progression free survival between OFL and OH groups. Log-Rank: χ2=3.68, P=0.0550.Fig. 2.: Overall survival between OFL and OH groups. Log-Rank: χ2=1.55, P=0.2127.Toxicity Major toxicities from both the OFL and the OH regimen were leukopenia and diarrhea. The overall incidence of leukopenia was 53.6% in the OFL group and 50% in the OH group; no significant difference was found between the two groups. The occurrence of anemia (51.8%) and diarrhea (60.7%) was significantly higher in OH group than the 19.6% and 46.4% found in the OFL group (P=0.001, P=0.015, respectively). Grade I to II liver function damage, renal function damage and peripheral neuropathy were observed after 9, 2 and 3 cycles in the OH group, respectively (Table 3). No patient deaths induced by chemotherapy were observed in the present study.Table 3: Comparison of the toxicity between OFL and OH groupsDISCUSSION HCPT, a Topoisomerase I (TOPO I) inhibitor and differentiation-inducing agent, can inactivate TOPO I and induce cancer cells to differentiate. Because it has a different mechanism from other cytotoxic agents, it is not easy to induce cross drug resistance to HCPT with other anticancer agents and it is effective for cancer cells with drug resistance.8,9 OXA, the third generation platinum analogue that induces DNA cross-link ages and apoptotsis of cancer cells, shows a higher activity in ACRC which has been proven to be resistant to cisplantin.10,11 The mechanism of the OH regimen is justified as follows: (1) The two drugs act at different phases of cell cycle and by different mechanisms and have no overlaping toxicity; (2) Because it inhibits TOPO I function, HCPT inhibits self-repair of cancer cells after DNA cross-linkages induced by OXA and enhances cytotoxicity of OXA; (3) Most patients in this study were previously treated with cisplantin and/or 5-Fu, and OXA and HCPT completely have no cross-resistance to those patients; (4) The depressed susceptibility to inductive apoptosis of colorectal adenocarcinoma may contribute to the initial phase of tumorigenesis.12 Our previous study has proven that OXA can enhance the role of HCPT in inducing the apoptosis of human colorectal cell line in vivo.4 Non-randomized studies of a combination of OXA and CPT-11 (IROX regimen) were administered to treat ACRC patients with prior exposure to 5-Fu and elicited RR of 34% and 37%,13,14 whereas RRs of 15% were produced with 5-Fu plus OXA or 4% with 5-Fu plus CPT-11 as the second line therapies.15 The results showed the RR of IROX regimen might be higher than 5-Fu plus OXA or CPT-11 for the 5-Fu resistance ACRC patients. Because HCPT and CPT-11 both belong to the semisynthetic campothecine agents and have the same mechanism of action during the same phase of the cell cycle, so the OH regimen may have a similar clinical efficacy. In this study 28 patients yielded 11 (39.28%) PR and 14 (50%) SD in the OH group versus 7 (25%) PR and 16 (57.14%) SD in the OFL group. Although the RR in the OH group was higher than that in the OFL group, there was no significant difference between the two groups (P=0.47). The 1-year survival rate and median PFS and OS in OH group were all higher than that in OFL group, but no significant differences were found between the two groups. In addition, 75% (6/8) of the patients with abdominal pain and 80% (4/5) with bowel obstruction in OH group were released over 4 weeks. This suggested that the OH regimen might relieve clinical complications and improve the quality of life for ACRC patients. The major dose-limiting toxicities of the OH regimen were myelosuppression and diarrhea. The incidence of grade III+IV leukopenia was 28.6% in the OH group, which is higher than that in OFL group but not statistically different. Because the nadir occurred between 7 and 13 days, we recommend WBC and BPC should be checked every other day from 5 days to 14 days after the OH regimen treatment. Diarrhea was found from day 1 to 11 at the onset of chemotherapy. The incidence of diarrhea in the OH group is significantly higher than that in OFL group (P=0.015). Diarrhea combined with leukopenia was observed in 14 cycles, including 11 cycles with grade III+IV leukopenia after OH regimen chemotherapy. Among 16 cycles with grade III diarrhea after the OH regimen chemotherapy, 6 cycles occurred with grade III leukopenia (37.5%) and 3 cycles with grade IV leukopenia (18.8%) and 2 patients with grade IV diarrhea had grade IV leukopenia (100%). These results suggested that grade III+IV diarrhea occured frequently with grade III+IV leukopenia at some time during the OH chemotherapy regimen. Although no infectious agents were found by routine stool examination in grade III+IV diarrhea patients, it is necessary to use G-CSF and antibiotic for those patients. Our results suggested the OH regimen, as a second-line treatment for ACRC especially for 5-Fu resistant patients, is well-tolerated. The major dose-limiting toxicities for OH regimen were grade III+IV leukopenia and diarrhea.